Kidney International Reports (Oct 2019)

Rationale and Design for a Phase 1 Study of N-Acetylmannosamine for Primary Glomerular Diseases

  • Marjan Huizing,
  • Tal Yardeni,
  • Federico Fuentes,
  • May C.V. Malicdan,
  • Petcharat Leoyklang,
  • Alexander Volkov,
  • Benjamin Dekel,
  • Emily Brede,
  • Jodi Blake,
  • Alva Powell,
  • Harish Chatrathi,
  • Yair Anikster,
  • Nuria Carrillo,
  • William A. Gahl,
  • Jeffrey B. Kopp

Journal volume & issue
Vol. 4, no. 10
pp. 1454 – 1462

Abstract

Read online

Introduction: Sialic acids are important contributors to the polyanionic component of the glomerular filtration barrier, which regulates permeability selectivity. Pathologic glomerular hyposialylation, associated with podocyte effacement, has been implicated in human and mouse glomerulopathies. Oral treatment with N-acetylmannosamine (ManNAc), the uncharged precursor of sialic acid, ameliorates glomerular pathology in different models of glomerular disease. Methods: Here we explore the sialylation status of kidney biopsies obtained from 27 subjects with various glomerular diseases using lectin histochemistry. Results: We identified severe glomerular hyposialylation in 26% of the biopsies. These preliminary findings suggest that this condition may occur relatively frequently and may be a novel target for therapy. We describe the background, rationale, and design of a phase 1 study to test safety, tolerability, and pharmacokinetics of ManNAc in subjects with primary podocyte diseases. Conclusion: We recently demonstrated that ManNAc was safe and well tolerated in a first-in-human phase 1 study in subjects with UDP-N-acetylglucosamine (GlcNAc) 2-epimerase/ManNAc kinase (GNE) myopathy, a disorder of impaired sialic acid synthesis. Using previous preclinical and clinical data, we propose to test ManNAc therapy for subjects with primary glomerular diseases. Even though the exact mechanisms, affected cell types, and pathologic consequences of glomerular hyposialylation need further study, treatment with this physiological monosaccharide could potentially replace or supplement existing glomerular diseases therapies. Keywords: glomerular hyposialylation, lectin histochemistry, ManNAc, podocytopathy, sialic acid